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Background: Data on efficacy of bevacizumab (B) beyond first-line taxane -including regimen (BT) as first-line
treatment are lacking. Although preclinical results that anti-angiogenic agents combined with hormonal therapy
(HT) could be active, no clinical data exist about combination of maintenance Bevacizumab (mBev) with HT.
Methods: Thirty-five patients who experienced a response after first-line BT, were given mBev at the dose of
15 mg/kg every 3 weeks. Among 30 pts with hormonal receptor-positive metastatic breast cancer (MBC), 20 (66.6%)
received HT with mBev (mHTBev). Objective of the study was the outcome and safety of mBev and in two groups
of patients receiving HT or not.
Results: Complete response and partial response was achieved/maintained in 4 (11.4%) and 13 (37.1%) patients,
respectively (overall response rate: 48.5%). Clinical benefit was obtained on 23 patients (65.7%). Median of mBev PFS
and clinical benefit were 6.8 months (95% CI: 0.8-12.7) and 17.1 months (95% CI :12.2-21.9), respectively. Median PFS
of patients who received mHTBev was longer than mBev without HT (13 months and 4.1 months, respectively,
p = 0.05). The most common severe toxicities were proteinuria (11.4%) and hypertension (8.5%). No additional
toxicity was observed with HTBev.
Conclusion: Maintenance bevacizumab with or without anti-hormonal therapy in patients with hormone receptor
positive breast cancer is tolerable and associated with long-term clinical outcome; these results encourage the
strategy of prolonging bevacizumab until progression in combination with anti-hormonal agents.
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Angiogenesis is one of the key mechanisms of tumor
growth and survival and is necessary for cancer rising, in-
vasion and metastatization. The mechanism of angiogeni-
sis is regulated by some pro-angiogenic factors such as the
vascular endothelial growth factor (VEGF) [1,2]. The
VEGF, over expressed in many tumors and associated with* Correspondence: alessandra.fabi@virgilio.it
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reproduction in any medium, provided the orpoor prognosis, is an attractive target for the development
of biological therapy [3,4]. Bevacizumab (AvastinW), a re-
combinant humanized monoclonal antibody directed
against VEGF, is currently approved for the treatment of
many solid tumors and it represents a valid option for
treatment of HER2-negative metastatic breast cancer
(mBC) patients [5,6]. In advanced disease, the efficacy of
first-line bevacizumab including chemotherapy has been
proven in three randomized clinical trials [7-9] and its ac-
tivity has been recently shown as second-line option [10].
Overall, the addition of bevacizumab to chemotherapy. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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higher objective response rates (RRs), without any im-
provement in overall survival (OS). Thus, every research
effort should be to improve the efficacy of every first-line
bevacizumab-including regimen.
An attractive option could be to continue the anti-
angiogenic agent as maintenance therapy in patients
who are responder to first-line bevacizumab-based
chemotherapy. This approach has an interesting preclin-
ical rationale derived from studies that have suggested
the power to increase tumor growth following with-
drawal of VEGF inhibitors. In fact, although the VEGF
inhibitors can destroy as much as 80% of tumor vascula-
ture, tumor vessels may rapidly re-grow after cessation
of treatment with these inhibitors [11,12]. Recently,
Mancuso et al. [13] have also shown that when tumors
in transgenic mouse were inhibited by VEGF tyrosine
kinase receptor the same tumors were completely re-
vascularized within the first week after stopping treat-
ment, indicating that surviving pericytes and the empty
sleeves of vascular basement membrane contributed to
the rapid restoration of the tumor vasculature.
These preclinical data and the emerging results in
advanced colo-rectal cancer [14,15], findings suggesting
the clinical benefit of bevacizumab beyond first-line
therapy due to permanent suppression of VEGF, could
be an assumption for the clinical use of the biological
agent as maintenance treatment also in mBC patients.
Preclinical models suggested that addition of anti-
vascular endothelial growth factor therapy could improve
the efficacy of anti-estrogens in hormone-sensitive breast
cancer [16]. Recently a phase II trial in advanced breast
cancer evaluated the feasibility and efficacy of bevacizu-
mab added to either anastrozole or fulvestrant in postme-
nopausal hormonal receptor-positive patients already
resistant to the adjuvant aromatase inhibitor. Both regi-
mens showed a good response rate and encouraging pro-
gression free survival (ORR 28%, median PFS 18 months)
without severe toxicity registered in both regimens [17].
In this study, we consecutively evaluated the safety
and activity of maintenance therapy with bevacizumab
alone or combined with endocrine therapy (HT), beyond
response or disease stabilization by first-line combined
chemotherapy (bevacizumab plus paclitaxel) in HER2-
negative mBC patients.
Methods
Study design
The primary objectives of this prospective and observa-
tional study were: 1) to evaluate the activity of two con-
secutive groups of women receiving bevacizumab as
maintenance (mBev) combined with hormonal therapy
or not; 2) to assess the activity mBev in MBC patients
responding to first-line paclitaxel-bevacizumab (BT).Secondary objectives were: 1) to assess the safety pro-
file of mBev; 2) to assess mBev progression free survival
(PFS), clinical benefit duration and overall survival
(mBev OS) of these MBC women.
Patient population
All data of this multicenter study were collected at the
Regina Elena National Cancer Institute in Rome. All
patients provided written informed consent before
undergoing any study-specific procedure. The study was
approved by the Local Ethic Committee (IFO, Regina
Elena Cancer Institute).
Patients eligibility
HER2-negative mBC patients were included and pro-
spectively followed. Patients were considered eligible if
they had histological diagnosis of breast cancer, had
metastatic disease, and had been never treated by
chemotherapy and/or bevacizumab for advanced disease.
Patients might have a Performance Status (ECOG) ≤ 2
and a life expectancy ≥ 3 months. Patients with previously
controlled neoplastic disease diagnosed over 5 years before
were allowed to enter the study. They were neither preg-
nant nor nursing. Patients with symptomatic central ner-
vous system metastases were excluded. They were required
to have a left ventricular ejection fraction (LVEF) of 50% or
greater, absolute neutrophil count more than 1500 x ll,
platelet count more than 100.000 x ll, bilirubin less than
2 mg/dl, AST/ALT less than 3 times the upper normal
limit (UNL). Other concurrent antineoplastic therapy was
not admitted and patients might have concluded any
radiotherapy or hormonal therapy at least 1 month before
treatment. Patients could receive concomitant bisphospho-
nate treatment.
Patients were given bevacizumab 10 mg/kg iv on day 1
and 15 plus Paclitaxel 80 mg/mq iv on day 1, 8, 15, every
28 days as first-line therapy. Cycles were continued at
discretion of investigator, but not interrupted before
6 cycles in case of response or stable disease. Assess-
ment was performed every three courses. In case of re-
sponse and/or stable disease, after 3 weeks of the last BT
cycle, patients were given mBev therapy at the dose of
15 mg/kg every 21 days with or without hormonal
agents, based on the expression of hormonal receptors.
Maintenance bevacizumab (associated to hormonal
treatment in hormonal receptors positive tumor) was
used until disease progression, excluding patient’s with-
drawal, unacceptable toxicity, deteriorated clinical condi-
tions or patient’s refusal. Exclusion criteria for the use of
maintenance hormonal therapy were as follows: patients
in premenopausal status who had previously received
tamoxifen as adjuvant treatment experiencing disease in
course of adjuvant hormonal therapy; previous intoler-
ance or onset of severe side effects to aromatase
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menopausal patients (history of thromboembolism, in-
tolerance, endometrial disease;); patients’ refusal.Table 1 Characteristics of 35 HER2 negative mBC patients
treated with Bevacizumab plus Paclitaxel followed by
maintenance Bevacizumab
Total number of patients (n = 35) Frequency (%)
Median age (range) 50 (32–72)
Menopausal Status
Pre 6 (17.1)
Post 29 (82.9)
Hormonal Receptor Status
Negative 5 (14.3)
Positive 30 (85.7)
Triple negative 5 (14.3)
Adjuvant chemotherapyStudy assessment
Evaluation of response was performed by Computed
Tomography scan. The response to BT, the response
to mBev, the mBev PFS (from the start of mBev to
the first tumor relapse), the duration of clinical benefit
(from the start of BT to the first relapse in course of
mBev), the overall survival (OS, from the start of BT
to death) were evaluated. RECIST criteria were used for
response evaluation[18].
Tumor response and survival status were followed
every 12 weeks both during BT treatment and mBev
therapy. Complete response (CR) was defined as dis-
appearance of all target lesions; partial response (PR) was
defined as ≥ 30% decrease in the sum of the largest diam-
eter of target lesions compared with the baseline; progres-
sive disease (PD) was defined as ≥ 20% increase in the sum
of the largest diameter of target lesions compared with the
sum of largest diameter recorded before treatment start.
Stable disease (SD) was defined as neither sufficient
shrinkage to qualify for complete or partial response nor
sufficient increase to qualify as progressive disease.
Information including demographics, medical history,
breast cancer history, and tumor biology was collected.
During treatment, all adverse events related to both BT
and mBev were recorded on the electronic case report
form. Data were collected for up to 12 months after the
last bevacizumab infusion for the following specific ad-
verse events previously reported in trials of bevacizumab:
hypertension; proteinuria; arterial and venous thrombo-
embolic events; congestive heart failure; central nervous
system bleeding; other hemorrhages; wound-healing
complications; gastrointestinal perforations and fistulae.
Additional information on haematological toxicity was
collected using incidence of National Cancer Institute
Common Toxicity Criteria for Adverse Events (NCI CTC
AE, version 3.0) [19].- None 13 (37.1)
- including anthracyclines 9 (25.7)
- including antracyclines + taxanes 9 (25.7)
- Other regimens 4 (11.4)
Adjuvant hormonal therapy 22 (62.8)
Visceral metastatic sites 23 (65.7)
Median Disease Free Survival, months (range) 30 (0–362)
Median Cycles of Bevacizumab + Paclitaxel (range) 8 (6–12)
Median cycles of three-weekly mBev (range) 7 (1 – 28)
Median PS at the start of mBev (range) 0 (0–1)
PS, Performance Status (ECOG); Triple negative, estrogen receptor, progesteron
receptor, HER2 negative; mBev, mainteinance Bevacizumab.Statistical analysis
All patients enrolled were considered in the intention-to-
treat population (ITT). This population was evaluated
both for the efficacy and safety analysis. Rate and median
times are reported with their 95% confidence interval to
better interpret data.
The time to event analysis was performed according
the Kaplan-Meier method and differences among curves
were evaluated by the log-rank test. SPSS software ver-
sion 17.0 was used for statistical analyses (SPSS, Inc.
Chicago, Ill.)Results
Patients characteristics
From July 2007 through May 2010, thirty-five patients
entered the study. Their characteristics are listed in Table 1.
The median age was 50 years (32–72) and 29 (82.9) patients
had postmenopausal status. Most of women (85.7%) had
tumors expressing hormonal receptors, twenty-two (62.8%)
patients had previously received adjuvant chemotherapy,
9 (25.7%) of them were administered regimens including a
taxane; 23 (65.7%) patients had visceral involvement.
All patients received the BT combination, for a median
of 8 cycles (6–12). In all cases the treatment was followed
by mBev. The median of mBev three-weekly cycles given
was 7 (1–28).
Among 30 patients with hormonal receptor-positive
mBC, mBEV combined with hormonal therapy (HT) was
given to 20 (66.6%) post-menopausal patients (19 of them
received an aromatase inhibitor and 1 tamoxifen); one of
the exclusion criteria for using maintenance HT was
present in the remained 10 hormonal receptor positive
patients.Efficacy of BT
All patients were evaluable for efficacy. Complete response
and partial response was achieved in 4 (11.4%) and 18
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of 62.8% (95%CI: 46.8-78.8); stable disease was shown in
13 (37.2%) patients.
Efficacy of maintenance Bevacizumab
All patients were evaluable for efficacy. CR and PR was
achieved/maintained in 4 (11.4%) and 13 (37.1%) patients,
respectively, for an overall response rate of 48.5%; ten
(28.6%) women experienced SD. Clinical benefit was
obtained on 23 patients (65.7%). Eight (22.9%) patients
progressed during mBev therapy.
Table 2 shows the activity of mBev according to re-
sponse to BT. All CRs achieved in course of BT treatment
were maintained during mBev; among 18 patients achiev-
ing PR by BT, 12 (66.6%) maintained responses during
mBev, while 6 (33.4%) experienced PD. Among 13
patients showing SD while on BT, PR, SD and PD in
course of mBev were obtained in 1 (7.7%), 10 (76.9%) and
2 (15.4%) patients, respectively.
The median mBev PFS was 6.8 months (95%CI: 0.8-12.7).
The median mBev PFS was 10.2 months among patients
who received a taxane as adjuvant treatment compared
with 6.6 months among patients who did not. At a median
follow up of 17.5 months (10–49), median duration of clin-
ical benefit was 17.1 months (95%CI :12.2-21.9). The me-
dian OS has not been reached yet.
Efficacy of maintenance Bevacizumab according to
hormonal therapy
Among patients given mBev plus anti-hormonal therapy
(HTBev), 12 (60%) patients responded to treatment in-
cluding 3 CR (15%) and 9 PR (45%). Stable disease was
achieved in 6 (30%) patients, while 2 (10%) experienced
PD. Among patients receiving mBev alone, 5 (33%)
achieved response, including 1 CR (6.6%) and 4 PR
(26.7%); stable and progression disease were seen in 4
(26.7%) and 6 (40%) patients, respectively.
Not all women who responded to BT and having
tumors expressing hormonal receptors were adminis-
tered HT as maintenance. The median mBev PFS of
patients given HTBev was 13 months (1-39+; 95%C.I.:
6.2-27.5), while the median mBev PFS of patients who
received only mBev was 4.1 months (1–15; 95%C.I.: 1.9-Table 2 Response to maintenance Bevacizumab (mBev)
according to activity of Bevacizumab plus Paclitaxel (BT)
Response mBev
Activity BT CR PR SD PD
n n (%) n (%) n (%) n (%)
4 CR 4 (100)
18 PR 12 (66.7) 6 (33.3)
13 SD 1 (7.7) 10 (76.9) 2 (15.4)
mBev, maintenance Bevacizumab; CR, complete response; PR, partial response;
SD, stable disease; PD, progression disease.6.2). A statistically significant difference in terms of PFS
was seen between these two groups of patients (p = 0.05)
[Figure 1].
Safety profile
The safety profile shown in all 35 patients during BT
and mBev therapy can be considered acceptable (Tables 3
and 4). Overall, the incidence of severe grade of adverse
events was higher during the maintenance therapy. The
most common effects reported with mBev treatment
were grade 2 (8.5%, in 2 HTBev and 1 bevacizumab
alone patients) and grade 3 proteinuria (11.4%, 1 HTBev
and 3 bevacizumab alone patients); grade 2 (5.7%, 1
HTBev and 1 bevacizumab alone patients) and grade 3
hypertension (8.5%, in 2 HTB and 1 bevacizumab alone
women). Only 1 patient, affected by grade 1 hyperten-
sion before entering the study, experienced a worsening
of the grade 3 hypertension. One case (bevacizumab
alone) of pneumonia was reported in course of mBev
therapy.
During the mBev, 3 (8.5%) and 4 (11.4%) patients dis-
continued treatment due to grade 3 hypertension and
proteinuria at a median of 10 cycles (4–28). No patient
resumed bevacizumab as maintenance treatment. All
patients, but one, recovered from toxicity.No additional
toxicity was observed in course of HTBev.
Discussion
The peculiarity of this report is that provides further
clinical results concerning the role of mBev in MBC
women experiencing a clinical benefit by first-line BT
combination. Moreover, no clinical finding has been
reported yet on maintenance bevacizumab associated
with hormonal therapy.
In the preclinical scenario, estrogen may play a key role
in the regulation of angiogenesis. A direct effect of endo-
crine therapy on tumor vasculature has been reported. In a
male mouse model of androgen-dependent breast cancer,
castration led to tumor shrinkage and vascular regression
[16]. However, endocrine resistance in this tumor model
was suggested by a wave of neo-vascularization and tumor
re-growth. On the other hand, endocrine castration initially
caused a reduction in VEGF mRNA levels while, at the time
of tumor re-growth, VEGF mRNA levels simultaneously
rebound. Moreover, data coming from retrospective studies
in patients with breast cancer indicated that high VEGF
levels in breast tumor tissue were associated with decreased
responsiveness to hormonal therapy in both adjuvant and
metastatic breast cancer patients [20,21]. Overall, these data
suggested that anti-VEGF therapy may delay or prevent the
onset of endocrine therapy resistance in patients with
hormone-sensitive breast cancer, supporting the use of the
combined therapy with anti-angiogenic plus anti-hormonal
agents in breast cancer. In our series, among patients with
Figure 1 Progression free survival (PFS) according to maintenace Bevacizumb (mBev) combined or not to hormonal therapy (HT) in
hormonal receptor positive patients.
Fabi et al. BMC Cancer 2012, 12:482 Page 5 of 7
http://www.biomedcentral.com/1471-2407/12/482tumors expressing hormonal receptors, a better mBev PFS
was seen when they were given an aromatase inhibitor plus
bevacizumab compared with those who did not received
any hormonal agent (mBev PFS 13 months vs 4.1 months,
p = 0.05),
To date, few data exist regarding the efficacy and safety
of bevacizumab as maintenance treatment in mBC. Smith
et al. [22] have recently reported a subgroup analyses in
patients enrolled in the Athena study who continued sin-
gle agent bevacizumab after stopping chemotherapy. They
found a median TTP and OS of 18.4 months and
30.0 months, respectively. In the majority of these
patients, maintenance bevacizumab was administered
alone for the extended periods and no informations were
given about use of bevacizumab plus HT in hormonal
receptors positive patients. In our prospective analysis on
HER2-negative breast cancer patients treated with mBev
beyond controlled disease after first-line BT therapy, theTable 3 Safety of Bevacizumab plus Paclitaxel (total
patients n = 35)
Toxicity Grade 1 Grade 2 Grade 3 Grade 4
n (%) n (%) n (%) n (%)
Bleeding 1 (2.8) - 1 (2.8) -
Protenuria - - - -
Hypertension - 2 (5.7) -
Neurotoxicity 1 (2.8) 2 (5.7) - -
LVS disfunction 1 (2.8) - - -ORr (CR + PR, 62.8%) resembled those reported in large
randomized phase III trials [7-9]. We administered beva-
cizumab in mBC beyond the end of chemotherapy until
disease progression or unacceptable toxicity. The main-
tenance therapy with bevacizumab was effective, report-
ing the ORr of 48.5%, the median mBev PFS of
6.8 months (95%CI 0.8-12.7) and the duration of clinical
benefit of 17.1 months (95%CI 12.2-21.9).
According to data coming from a recent meta-analysis,
it could also be of interest that prior treatment with ad-
juvant taxanes was predictive of better mBev PFS [23].
In our analysis, the median mBev PFS was 10.2 months
among patients who received a taxane as adjuvant treat-
ment compared with 6.6 months among those who did
not (P = 0.57). These findings are strengthen by the use
of bevacizumab plus paclitaxel as first-line treatment
also in women previously administered adjuvant taxane-
including treatments.Table 4 Safety of maintenance-Bevacizumab (total
patients n = 35)
Toxicity Grade 1 Grade 2 Grade 3 Grade 4
n (%) n (%) n (%) n (%)
Bleeding 2 (5.7) - -
Protenuria - 3 (8.5) 4 (11.4) -
Hypertension 1 (2.8) 2 (5.7) 3 (8.5) -
Neurotoxicity 1 (2.8) - - -
LVS disfunction 1 (2.8) - - -
Other events Pneumonia 1 (2.8)
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and include arterial thrombosis, wound-healing compli-
cations, gastrointestinal GI perforation, bleeding, hyper-
tension, and proteinuria. A recent meta-analysis [24] of
randomized, controlled bevacizumab-containing trials
reported all grade hypertension in 3%to 36%of patients
and proteinuria in 21%to 63%of patients with nephrotic-
range proteinuria up to 2%of patients. The degree of
proteinuria was bevacizumab dose-dependent. The
pathogenesis of bevacizumab-associated hypertension
and renal toxicity is poorly understood; however, one
clinical study has suggested an association between these
two adverse events [25]. An interesting explanation of
the higher rate of proteinuria is that the continued in-
hibition of local VEGF in glomerular podocytes, as
occurs in the prolonged bevacizumab treatment, leads to
renal thrombotic microangiopathy, which causes the
final event of proteinuria [26]. In our study, no evidence
of increased risk of developing severe toxicities with
longer bevacizumab treatment was reported, except for
hypertension and proteinuria. According to data
reported by Smith et al. (22), the onset of grade 3 pro-
teinuria was common in the maintenance period. Similar
findings were observed in advanced ovarian cancer, in
patients receiving bevacizumab for prolonged time, after
treatment with carboplatin, paclitaxel and bevacizumab
[27]. In our study all patients recovered proteinuria tox-
icity after 2 weeks of bevacizumab discontinuation and
all patients continued treatment. Grade 3 hypertension
was infrequent (8.5%) and in that cases bevacizumab
was continued in association with antihypertensive ther-
apy. Adding hormonal therapy to bevacizumab did not
cause any further toxicity.
Our study, despite the small number of patients, is the
first prospective report on the activity and feasibility of a
maintenance combination of bevacizumab with hormo-
nal therapy in bevacizumab-pretreated women. In ab-
sence of data comparing association of HTBev versus
HT alone, our study could be the basis for a comparison
trial. Unfortunately, some questions remain still un-
answered: 1) What are the most useful biomarkers to
predict the efficacy during bevacizumab treatment? 2)
What is the optimal subset of patients could benefit by
mBev? 3) Is there the optimal hormonal treatment to
combine with bevacizumab?
In the Athena trial, some studies explored potential bio-
markers for bevacizumab, but more investigations are
warranted. In the meantime, further studies including
large number of patients, evaluation of their characteris-
tics and analysis of response to previous antiangiogenic
agents are needed, in order to select women who could
benefit by mBev. Another missing information is the role
of bevacizumab beyond progression, an issue that hope-
fully will be addressed by the ongoing TANIA study [28].Conclusions
Our results confirm that the strategy of prolonging the
use of bevacizumab until progression is tolerable and
often associated with encouraging long-term clinical out-
comes. Moreover, based on the results coming from our
series, in postmenopausal patients with hormone
receptor-positive HER2-negative mBC, treatment with
bevacizumab plus hormone therapy is feasible and effect-
ive, the most common treatment-related adverse events
remaining hypertension and proteinuria, a toxicity profile
which resembles that exerted by bevacizumab alone. Our
findings support the use of the combination of bevacizu-
mab plus anti-hormonal agents after bevacizumab plus
paclitaxel in this setting of patients. However, considering
the limits in terms of our analysis further investigations
are needed in order to conclusively clarify this issue.
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